Y Intercept Hong Kong Ltd Buys 2,769 Shares of Janux Therapeutics, Inc. $JANX

Y Intercept Hong Kong Ltd increased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 15.5% during the second quarter, HoldingsChannel.com reports. The firm owned 20,602 shares of the company’s stock after buying an additional 2,769 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Janux Therapeutics were worth $476,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Allspring Global Investments Holdings LLC grew its holdings in shares of Janux Therapeutics by 54.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 9,033 shares of the company’s stock worth $244,000 after purchasing an additional 3,168 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Janux Therapeutics by 13.3% in the first quarter. Bank of New York Mellon Corp now owns 89,370 shares of the company’s stock valued at $2,413,000 after acquiring an additional 10,511 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Janux Therapeutics by 6.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,855 shares of the company’s stock worth $320,000 after purchasing an additional 727 shares during the last quarter. New York State Common Retirement Fund raised its position in shares of Janux Therapeutics by 3.0% during the 1st quarter. New York State Common Retirement Fund now owns 16,435 shares of the company’s stock valued at $444,000 after acquiring an additional 471 shares during the last quarter. Finally, Victory Capital Management Inc. grew its position in shares of Janux Therapeutics by 9.6% during the 1st quarter. Victory Capital Management Inc. now owns 265,651 shares of the company’s stock worth $7,173,000 after buying an additional 23,242 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

JANX opened at $28.66 on Friday. The company has a market capitalization of $1.72 billion, a PE ratio of -15.92 and a beta of 2.83. The business has a fifty day simple moving average of $25.03 and a 200 day simple moving average of $25.29. Janux Therapeutics, Inc. has a 1 year low of $21.73 and a 1 year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.21. The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $3.07 million. Equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

JANX has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Wednesday, October 8th. Guggenheim assumed coverage on Janux Therapeutics in a report on Wednesday, September 3rd. They set a “buy” rating and a $72.00 target price for the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $45.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, September 10th. Raymond James Financial assumed coverage on Janux Therapeutics in a research report on Friday, July 11th. They issued an “outperform” rating and a $65.00 target price on the stock. Finally, Barclays began coverage on shares of Janux Therapeutics in a research note on Wednesday, September 17th. They set an “overweight” rating and a $47.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $79.08.

Insiders Place Their Bets

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 16,665 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $30.06, for a total value of $500,949.90. Following the completion of the sale, the insider owned 82,139 shares of the company’s stock, valued at approximately $2,469,098.34. This trade represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 8.10% of the company’s stock.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.